科兴制药：GB19注射液获得药物临床试验批准通知书

Core Viewpoint - The article highlights that Sinovac Biotech (688136.SH) has received approval from the National Medical Products Administration for its innovative drug "GB19 Injection," which targets BDCA2 for clinical trials, potentially offering new treatment options for autoimmune diseases [1] Group 1: Company Developments - Sinovac's wholly-owned subsidiary, Shenzhen Sinovac Biotech Co., Ltd., has been granted a Clinical Trial Approval Notice for GB19 Injection [1] - The drug targets plasmacytoid dendritic cells (pDC) by specifically binding to the BDCA2 target, differing significantly from existing clinical drugs that target B cell pathways [1] Group 2: Drug Mechanism and Potential - GB19 Injection works by inhibiting pDC cells from producing type I interferons, thereby intervening in the abnormal activation loop between innate and adaptive immunity [1] - Preclinical studies of GB19 have shown good in vitro activity, high immunogenicity, and a biological availability that maintains target inhibition for over 90 days, with excellent safety profiles [1] - If successfully developed, GB19 could provide new treatment options for patients with autoimmune diseases related to abnormal interferon pathways, such as systemic lupus erythematosus (SLE) [1]